AZD4831 (AstraZeneca) is an oral covalent myeloperoxidase (MPO) inhibitor being developed for heart failure. Almost half of chronic heart disease patients suffer from heart failure with a preserved ejection fraction (HFpEF) and have an estimated five-year mortality rate of 75% . Improvement in vascular structure could help these [...]
5 minute read
Sep. 28, 2022
AZD4831: an Oral Covalent Myeloperoxidase (MPO) Inhibitor for Heart Failure
AZD4831
oral MPO covalent inhibitor Ph. IIb/III candidate in HFpEF previous literature and selectivity opt J. Med. Chem. AstraZeneca, Gothenburg, SE